New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
11:38 EDTDDS, PSTI, EBIX, GGB, AWAYHigh option volume stocks: GGB PSTI AWAY EBIX DDS
News For GGB;PSTI;AWAY;EBIX;DDS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
10:37 EDTAWAYOptions with decreasing implied volatility
Subscribe for More Information
05:30 EDTPSTIPluristem announce data showing PLX-R18 cells improve bone marrow transplant
Subscribe for More Information
February 27, 2015
10:32 EDTAWAYOptions with decreasing implied volatility
Subscribe for More Information
February 26, 2015
10:36 EDTAWAYOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTAWAYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
February 25, 2015
18:24 EDTAWAYOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTAWAYHomeAway initiated with an Underweight at Morgan Stanley
Subscribe for More Information
10:37 EDTAWAYOptions with decreasing implied volatility
Options with decreasing implied volatility: FUEL GREK NLNK HLSS SLXP LL VNDA AWAY DWA TRUE
08:24 EDTAWAYHomeAway trends, drivers strong, says Pacific Crest
After HomeAway reported stronger than expected Q4 results, Pacific Crest believes that the company's underlying trends, excluding negative currency impacts, are good. The firm says that the company's prices continue to be strong, while its results can beat expectations going forward. It keeps an Outperform rating on the shares.
February 24, 2015
16:08 EDTAWAYHomeAway sees FY15 revenue $510M-$520M, consensus $527.6M
Subscribe for More Information
16:07 EDTAWAYHomeAway sees Q1 revenue $119M-$120.5M, consensus $122.8M
Subscribe for More Information
16:06 EDTAWAYHomeAway reports Q4 EPS 0c, consensus 13c
Subscribe for More Information
February 23, 2015
18:02 EDTDDSOn The Fly: After Hours Movers
Subscribe for More Information
16:10 EDTDDSDillard's plans to open three new stores in FY15
Subscribe for More Information
16:09 EDTDDSDillard's reports Q4 EPS $3.17, consensus $3.18
Reports Q4 revenue $2.18B, consensus $2.08B. Reports a 3% increase in comparable store sales and a 103 basis point improvement in retail gross margin.
14:24 EDTAWAYHomeAway volatility elevated into Q4 and outlook
Subscribe for More Information
February 19, 2015
12:50 EDTPSTIPluristem says NIH study of PLX-R18 statistically significant
Pluristem Therapeutics announced the results of a recently completed trial conducted by the U.S. National Institutes of Health to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster. Injection of PLX-R18 cells into muscle, as compared to a placebo, resulted in a statistically significant improvement in the recovery of white blood cell, red blood cell, and platelet levels in animals exposed to high levels of radiation, the company said. It added, "The data also suggested that the treatment may potentially be able to shorten time to recovery."
February 18, 2015
09:10 EDTPSTIOn The Fly: Pre-market Movers
Subscribe for More Information
05:17 EDTPSTIPluristem Therapeutics reports 'significant' findings in NIH trial of PLX-R18
Pluristem Therapeutics announced the positive results of a recently completed trial conducted by the U.S. National Institutes of Health, or NIH, to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster. Injection of PLX-R18 cells into muscle, as compared to a placebo, resulted in a statistically significant improvement in the recovery of white blood cell, red blood cell, and platelet levels in animals exposed to high levels of radiation. The data also suggested that the treatment may potentially be able to shorten time to recovery. High levels of radiation can destroy the body's ability to produce these three blood lineages, and rapidly regaining that capacity is a key factor in surviving the hematologic component of acute radiation syndrome, or ARS, a condition caused by high-dose irradiation that can involve severe, sometimes lethal damage to the bone marrow as well as other physiologic systems and organs. The objective of this latest trial was to investigate the mechanism of action behind the significant improvement in survival in irradiated mice treated with PLX-R18 that was demonstrated in the NIH's first efficacy study. The results of the current study indicate that intramuscular administration exerts a systemic healing effect on bone marrow, lending further support to the concept that Pluristem's cells work systemically via secretion of therapeutic proteins, although the cells themselves remain in the muscle into which they were initially injected. While additional animal trials are needed prior to FDA approval of PLX-R18 for use in ARS, no human trials would be required because product development is conducted under the FDA's Animal Rule.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use